AG-221 Now Being Evaluated in Broad Range of Cancers.
Initial results suggest that COTI-2 has potential for another unmet cancer need.
Omeros Corporation (NASDAQ: OMER) provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease.
Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced entering a collaboration with the Charcot-Marie-Tooth Association ( …
Beth Goodier, 20, is one of only 40 people in the United Kingdom and about 1,000 worldwide who suffered from Kleine-Levin syndrome, a debilitating sleep disorder that renders her helpless for weeks …
UNMC researcher William Rizzo, M.D., has received a five-year, $3.3 million grant to study 10 rare diseases that affect children beginning in infancy or early childhood and throughout their life.
Birt-Hogg-Dubé syndrome (BHD)
A blog dedicated to the bone cancer.
Copyright © 2006-2014 CheckOrphan. All rights reserved.
CheckOrphan is a 501(c)(3) nonprofit organization. Contributions to CheckOrphan in the United States and Switzerland are tax-exempt to the extent provided by law.
Powered by GetReelHealth.com
Copyright © 2005-2014